Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials

Narjust Duma, Tariq Azam, Irbaz Bin Riaz, Miguel Gonzalez-Velez, Sikander Ailawadhi, Ronald Go

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Multiple myeloma (MM) occurs in all races, but the incidence in non-Hispanic black patients (NHBs) is two to three times higher than in non-Hispanic white patients (NHWs). We determined the representation of minorities and elderly patients in MM clinical trials. Enrollment data from all therapeutic trials reported in ClinicalTrials.gov from 2000 to 2016 were analyzed. Enrollment fraction (EF) was defined as the number of trial enrollees divided by the 2014 MM prevalence. Participation in MM clinical trials varied significantly across racial and ethnic groups; NHWs were more likely to be enrolled in clinical trials (EF 0.18%) than NHBs (EF 0.06%, p<.0001) and Hispanic patients (EF 0.04%, p<.0001). The median age of trial participants was 62 years, with 7,956 participants (66%) being less than 65 years of age. Collaborations between investigators, sponsors, and the community are necessary to increase access to clinical trials to our minority and elderly patients.

Original languageEnglish (US)
JournalOncologist
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Multiple Myeloma
Clinical Trials
Hispanic Americans
Ethnic Groups
Research Personnel
Incidence
Therapeutics

Keywords

  • Clinical trials
  • Elderly
  • Hematologic malignancies
  • Minorities
  • Multiple myeloma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials. / Duma, Narjust; Azam, Tariq; Riaz, Irbaz Bin; Gonzalez-Velez, Miguel; Ailawadhi, Sikander; Go, Ronald.

In: Oncologist, 01.01.2018.

Research output: Contribution to journalArticle

Duma, Narjust ; Azam, Tariq ; Riaz, Irbaz Bin ; Gonzalez-Velez, Miguel ; Ailawadhi, Sikander ; Go, Ronald. / Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials. In: Oncologist. 2018.
@article{6270bc6b2fce4dd7974e5ba93408d018,
title = "Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials",
abstract = "Multiple myeloma (MM) occurs in all races, but the incidence in non-Hispanic black patients (NHBs) is two to three times higher than in non-Hispanic white patients (NHWs). We determined the representation of minorities and elderly patients in MM clinical trials. Enrollment data from all therapeutic trials reported in ClinicalTrials.gov from 2000 to 2016 were analyzed. Enrollment fraction (EF) was defined as the number of trial enrollees divided by the 2014 MM prevalence. Participation in MM clinical trials varied significantly across racial and ethnic groups; NHWs were more likely to be enrolled in clinical trials (EF 0.18{\%}) than NHBs (EF 0.06{\%}, p<.0001) and Hispanic patients (EF 0.04{\%}, p<.0001). The median age of trial participants was 62 years, with 7,956 participants (66{\%}) being less than 65 years of age. Collaborations between investigators, sponsors, and the community are necessary to increase access to clinical trials to our minority and elderly patients.",
keywords = "Clinical trials, Elderly, Hematologic malignancies, Minorities, Multiple myeloma",
author = "Narjust Duma and Tariq Azam and Riaz, {Irbaz Bin} and Miguel Gonzalez-Velez and Sikander Ailawadhi and Ronald Go",
year = "2018",
month = "1",
day = "1",
doi = "10.1634/theoncologist.2017-0592",
language = "English (US)",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",

}

TY - JOUR

T1 - Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials

AU - Duma, Narjust

AU - Azam, Tariq

AU - Riaz, Irbaz Bin

AU - Gonzalez-Velez, Miguel

AU - Ailawadhi, Sikander

AU - Go, Ronald

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Multiple myeloma (MM) occurs in all races, but the incidence in non-Hispanic black patients (NHBs) is two to three times higher than in non-Hispanic white patients (NHWs). We determined the representation of minorities and elderly patients in MM clinical trials. Enrollment data from all therapeutic trials reported in ClinicalTrials.gov from 2000 to 2016 were analyzed. Enrollment fraction (EF) was defined as the number of trial enrollees divided by the 2014 MM prevalence. Participation in MM clinical trials varied significantly across racial and ethnic groups; NHWs were more likely to be enrolled in clinical trials (EF 0.18%) than NHBs (EF 0.06%, p<.0001) and Hispanic patients (EF 0.04%, p<.0001). The median age of trial participants was 62 years, with 7,956 participants (66%) being less than 65 years of age. Collaborations between investigators, sponsors, and the community are necessary to increase access to clinical trials to our minority and elderly patients.

AB - Multiple myeloma (MM) occurs in all races, but the incidence in non-Hispanic black patients (NHBs) is two to three times higher than in non-Hispanic white patients (NHWs). We determined the representation of minorities and elderly patients in MM clinical trials. Enrollment data from all therapeutic trials reported in ClinicalTrials.gov from 2000 to 2016 were analyzed. Enrollment fraction (EF) was defined as the number of trial enrollees divided by the 2014 MM prevalence. Participation in MM clinical trials varied significantly across racial and ethnic groups; NHWs were more likely to be enrolled in clinical trials (EF 0.18%) than NHBs (EF 0.06%, p<.0001) and Hispanic patients (EF 0.04%, p<.0001). The median age of trial participants was 62 years, with 7,956 participants (66%) being less than 65 years of age. Collaborations between investigators, sponsors, and the community are necessary to increase access to clinical trials to our minority and elderly patients.

KW - Clinical trials

KW - Elderly

KW - Hematologic malignancies

KW - Minorities

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=85046013985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046013985&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2017-0592

DO - 10.1634/theoncologist.2017-0592

M3 - Article

C2 - 29700207

AN - SCOPUS:85046013985

JO - Oncologist

JF - Oncologist

SN - 1083-7159

ER -